ABSTRACT
Lung transplantation is increasingly practiced for patients with end-stage lung disease. The successful outcome of solid organ transplantation today is severely impeded by the production of alloantibodies, mainly directed against the protein products of the HLA complex of the organ donor. While the association between antibody mediated rejection and allograft damage has been well established in renal and heart transplantation, it has not yet been well characterized in lung transplantation. This review addresses the question of HLA matching in lung transplantation and current knowledge of the allogenicity of different HLA class I and II antigens. The role of the antibody mediated immune response is discussed as well as the importance of pre-transplant or de novo post-transplant circulating antibodies. Finally, potential mechanisms, which may act individually or in combination, of antibody mediated damage to solid organ transplants are considered.
Subject(s)
Graft Rejection/immunology , HLA Antigens/immunology , Isoantibodies/blood , Lung Transplantation/adverse effects , Histocompatibility Testing , Humans , Isoantibodies/immunology , Tissue DonorsABSTRACT
Crataegus oxyacantha (Aubepine, Hawthorn), was used by european herbalist in the first century A. D. It went out fashion as a medicine until the 19th century for heart disease. The leaves, flowers, and berries of hawthorn contain a variety of bioflavonoid-like complexes that appear to be primarily responsible for the cardiac actions of the plant. Bioflavonoids found in C. oxyacantha include oligomeric procyanidins (OPCc), vitexin, quercetin, and hyperoside. The action of these compounds on the cardiovascular system has led to the development of leaf and flower extracts. As described in French pharmacopea, the hyperoside is the marker for quality control.
